aTyr Pharma, Inc.

DB:471A Stock Report

Market Cap: €250.0m

aTyr Pharma Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Sanjay Shukla

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage43.2%
CEO tenure7yrs
CEO ownership0.2%
Management average tenure5.9yrs
Board average tenure15.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sanjay Shukla's remuneration changed compared to aTyr Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$54m

Dec 31 2023US$1mUS$561k

-US$50m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$2mUS$561k

-US$45m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$41m

Mar 31 2022n/an/a

-US$39m

Dec 31 2021US$2mUS$510k

-US$34m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$29m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$1mUS$470k

-US$16m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$664kUS$450k

-US$24m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$30m

Dec 31 2018US$1mUS$450k

-US$35m

Sep 30 2018n/an/a

-US$40m

Jun 30 2018n/an/a

-US$44m

Mar 31 2018n/an/a

-US$45m

Dec 31 2017US$2mUS$403k

-US$48m

Compensation vs Market: Sanjay's total compensation ($USD1.30M) is above average for companies of similar size in the German market ($USD786.80K).

Compensation vs Earnings: Sanjay's compensation has been consistent with company performance over the past year.

CEO

Sanjay Shukla (52 yo)

7yrs

Tenure

US$1,300,525

Compensation

Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...

Leadership Team

NamePositionTenureCompensationOwnership
Sanjay Shukla
President7yrsUS$1.30m0.16%
€ 406.6k
Jill Broadfoot
Chief Financial Officer6.3yrsUS$677.84k0.025%
€ 62.0k
Nancy E. Krueger
General Counsel & Corporate Secretary10.1yrsUS$651.28k0.027%
€ 66.3k
Xiang-Lei Yang
Founderno datano datano data
Jayant Aphale
Vice President of Technical Operationsless than a yearno datano data
Ashlee Dunston
Director of Investor Relations & Corporate Communicationsno datano datano data
Peter Villiger
Vice President of Corporate Development4.8yrsno datano data
Danielle Campbell
VP of Human Resource2.9yrsno datano data
Leslie Nangle
Vice President of Researchno datano datano data
Ying Buechler
Executive Director of Biologics Development & Manufacturingno datano datano data
David King
Scientific Consultant5.9yrsUS$717.31kno data

5.9yrs

Average Tenure

62yo

Average Age

Experienced Management: 471A's management team is seasoned and experienced (5.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sanjay Shukla
President7yrsUS$1.30m0.16%
€ 406.6k
John Clarke
Independent Director19.2yrsUS$120.84k0.024%
€ 58.9k
Paul Schimmel
Independent Director19.2yrsUS$61.20k1.31%
€ 3.3m
Floyd Bloom
Member of Scientific Advisory Board15.1yrsno datano data
Bruce Beutler
Member of Scientific Advisory Board15.3yrsno datano data
Benjamin Cravatt
Member of Scientific Advisory Boardno datano datano data
Timothy Coughlin
Independent Chairman of the Board7.6yrsUS$92.20k0.067%
€ 166.8k
Osamu Nureki
Member of Scientific Advisory Board15.2yrsno datano data
Susan Ackerman
Member of Scientific Advisory Boardno datano datano data
Wing Wong
Member of Scientific Advisory Boardno datano datano data
Nancy Ip
Member of Scientific Advisory Boardno datano datano data
Jane Gross
Independent Director5.3yrsUS$68.88k0.0072%
€ 17.9k

15.1yrs

Average Tenure

67yo

Average Age

Experienced Board: 471A's board of directors are seasoned and experienced ( 15.1 years average tenure).